Cargando…

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

BACKGROUND: Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC). Few treatment options are available for NSCLC patients who have responded to gefitinib treatment and demonstrated tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Satoshi, Tanaka, Junta, Ota, Takeshi, Kondo, Rie, Tanaka, Hiroshi, Kagamu, Hiroshi, Ichikawa, Kosuke, Koshio, Jun, Baba, Junko, Miyabayashi, Takao, Narita, Ichiei, Yoshizawa, Hirohisa
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022883/ https://www.ncbi.nlm.nih.gov/pubmed/21194487 http://dx.doi.org/10.1186/1471-2407-11-1

Ejemplares similares

Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors
por: Sato, Ko, et al.
Publicado: (2016)

Henoch Schönlein purpura associated with pulmonary adenocarcinoma
por: Mifune, Daiki, et al.
Publicado: (2011)

Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells
por: Tanaka, Tomohiro, et al.
Publicado: (2017)

DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations
por: Nozaki, Koichiro, et al.
Publicado: (2014)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy
por: Watanabe, Satoshi, et al.
Publicado: (2020)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Determination of specific life changes on psychological distress during the COVID-19 pandemic
por: Kabasawa, Keiko, et al.
Publicado: (2021)

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients
por: Kushiro, Kohei, et al.
Publicado: (2022)

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events
por: Fujisaki, Toshiya, et al.
Publicado: (2021)

Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease
por: Sato, Yusuke, et al.
Publicado: (2021)

Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)
por: Shoji, Satoshi, et al.
Publicado: (2022)

Study Design and Baseline Profiles of Participants in the Uonuma CKD Cohort Study in Niigata, Japan
por: Kabasawa, Keiko, et al.
Publicado: (2020)

Association of metabolic syndrome traits with urinary biomarkers in Japanese adults
por: Kabasawa, Keiko, et al.
Publicado: (2022)

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
por: Watanabe, Satoshi, et al.
Publicado: (2014)

Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report
por: Lee, Su Jin, et al.
Publicado: (2012)

Association of estimated dietary acid load with albuminuria in Japanese adults: a cross-sectional study
por: Kabasawa, Keiko, et al.
Publicado: (2019)

Timing of retreatment for patients with previously coiled or clipped intracranial aneurysms: Analysis of 156 patients with multiple treatments
por: Okada, Takeshi, et al.
Publicado: (2016)

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations
por: Jiang, Xuhong, et al.
Publicado: (2020)

Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors
por: Kadowaki, Hiroshi, et al.
Publicado: (2021)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401)
por: Okajima, Masaaki, et al.
Publicado: (2021)

Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study
por: Shoji, Satoshi, et al.
Publicado: (2019)

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
por: Hashimoto, Kosuke, et al.
Publicado: (2020)

Education, household income, and depressive symptoms in middle-aged and older Japanese adults
por: Hinata, Aya, et al.
Publicado: (2021)

Rhabdomyolysis Caused by Gefitinib Overdose
por: Obayashi, Shohei, et al.
Publicado: (2021)

Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
por: Sugiura, Ayumi, et al.
Publicado: (2020)

Photoprocesses of the tyrosine kinase inhibitor gefitinib: from femtoseconds to microseconds and from solution to cells
por: Tamarit, Lorena, et al.
Publicado: (2021)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity
por: Naruo, Yoshimi, et al.
Publicado: (2011)

The Preston Retreat
Publicado: (1889)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
por: Uchida, Takahiro, et al.
Publicado: (2019)

Fracture Resistance of Retreated Roots Using Different Retreatment Systems
por: Er, Kursat, et al.
Publicado: (2011)

Evidence for safety of retreatment with a single intra-articular injection of Gel-200 for treatment of osteoarthritis of the knee from the double-blind pivotal and open-label retreatment clinical trials
por: Strand, Vibeke, et al.
Publicado: (2016)

Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
por: Andersson, Mattias K, et al.
Publicado: (2008)

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
por: Okubo, S, et al.
Publicado: (2004)

Retreats : handmade hideaways to refresh the spirit
por: Drinkard, G. Lawson, 1951-
Publicado: (1997)

Spontaneous aspiration of a long tree twig as foreign body
por: Hashimoto, Kosuke, et al.
Publicado: (2019)

Sudden intraoperative pulmonary congestion in a patient with severe anemia transfused 3 days prior to surgery
por: Shimizu, Takeru, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_usfn1kh08s05ef71go9bl85fni